Arrowstreet Capital
TXG icon

Arrowstreet Capital’s 10x Genomics TXG Stock Holding History

Arrowstreet Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,680
Closed -$256K – 2100
2025
Q4 		$256K Buy
+15,680
New +$237K ﹤0.01% 1759
2025
Q3 		– Sell
-123,604
Closed -$1.43M – 2116
2025
Q2 		$1.43M Buy
123,604
+107,023
+645% +$976K ﹤0.01% 1529
2025
Q1 		$145K Buy
+16,581
New +$209K ﹤0.01% 1754
2022
Q3 		– Sell
-5,846
Closed -$265K – 1465
2022
Q2 		$265K Buy
+5,846
New +$303K ﹤0.01% 1139
2021
Q4 		– Sell
-27,100
Closed -$3.94M – 1733
2021
Q3 		$3.94M Buy
27,100
+4,500
+20% +$773K ﹤0.01% 986
2021
Q2 		$4.43M Buy
+22,600
New +$4.09M 0.01% 1108
2021
Q1 		– Sell
-2,600
Closed -$368K – 2544
2020
Q4 		$368K Sell
2,600
-41,166
-94% -$5.97M ﹤0.01% 2078
2020
Q3 		$5.46M Sell
43,766
-32,900
-43% -$3.45M 0.01% 1109
2020
Q2 		$6.85M Buy
+76,666
New +$5.97M 0.01% 933

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's TXG Position: Q1 2026 in Review

Arrowstreet Capital sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 15,680 shares — an estimated $256K sold.

Arrowstreet Capital first reported a position in TXG in Q2 2020 and held it in 9 quarters. The position peaked at $6.85M in Q2 2020. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Arrowstreet Capital reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 15,680 10x Genomics shares in Q1 2026, an estimated $256K.
  • Arrowstreet Capital first reported a position in 10x Genomics in Q2 2020 and held it in 9 quarters.
  • Arrowstreet Capital's 10x Genomics position peaked at $6.85M in Q2 2020.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.